Labopharm May Conduct Additional Trial To Support Tramadol NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
U.S. regulators questioned Labopharm’s statistical methods in a May 30 “approvable” letter, the opioid analgesic’s second.
You may also be interested in...
Labopharm Submits Complete Response For Tramadol
Canadian specialty pharma now awaits new action date for delayed once-daily analgesic, already launched in 12 other countries.
Labopharm Submits Complete Response For Tramadol
Canadian specialty pharma now awaits new action date for delayed once-daily analgesic, already launched in 12 other countries.
FDA Rejects Labopharm Appeal On Once-Daily Tramadol
Canadian drug maker says it plans to appeal to the next supervisory level at the FDA.